
STERIS plc (NYSE:STE - Free Report) - Analysts at Zacks Research cut their Q3 2027 earnings per share estimates for STERIS in a research note issued on Monday, July 14th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.90 per share for the quarter, down from their prior estimate of $2.92. The consensus estimate for STERIS's current full-year earnings is $9.08 per share.
Several other analysts have also recently issued reports on STE. Needham & Company LLC restated a "hold" rating on shares of STERIS in a research note on Monday, April 7th. Morgan Stanley raised STERIS from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $260.00 to $276.00 in a report on Tuesday. Citigroup reaffirmed an "outperform" rating on shares of STERIS in a report on Friday, May 16th. JMP Securities upped their target price on STERIS from $265.00 to $280.00 and gave the company a "market outperform" rating in a report on Friday, May 16th. Finally, Jefferies Financial Group assumed coverage on STERIS in a report on Thursday, May 29th. They set a "hold" rating and a $263.00 target price for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, STERIS has an average rating of "Moderate Buy" and an average price target of $266.50.
Check Out Our Latest Report on STERIS
STERIS Stock Down 1.5%
NYSE STE traded down $3.34 on Thursday, hitting $224.28. 1,076,141 shares of the stock traded hands, compared to its average volume of 558,339. The stock has a 50-day moving average of $238.72 and a 200 day moving average of $226.41. STERIS has a twelve month low of $200.98 and a twelve month high of $252.79. The company has a market capitalization of $22.06 billion, a P/E ratio of 36.17 and a beta of 0.92. The company has a current ratio of 1.96, a quick ratio of 1.39 and a debt-to-equity ratio of 0.29.
STERIS (NYSE:STE - Get Free Report) last issued its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.15. STERIS had a return on equity of 14.21% and a net margin of 11.26%. The company had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.47 billion. During the same quarter in the prior year, the business earned $2.58 earnings per share. The company's revenue was up 5.7% compared to the same quarter last year.
Institutional Investors Weigh In On STERIS
Institutional investors and hedge funds have recently modified their holdings of the stock. Select Equity Group L.P. lifted its holdings in shares of STERIS by 165.3% in the fourth quarter. Select Equity Group L.P. now owns 2,599,730 shares of the medical equipment provider's stock valued at $534,400,000 after purchasing an additional 1,619,796 shares in the last quarter. Orbis Allan Gray Ltd purchased a new stake in shares of STERIS in the first quarter valued at $349,950,000. Norges Bank purchased a new stake in shares of STERIS in the fourth quarter valued at $238,836,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of STERIS by 55.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,520,479 shares of the medical equipment provider's stock valued at $344,617,000 after purchasing an additional 540,999 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of STERIS by 9.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 5,439,349 shares of the medical equipment provider's stock valued at $1,232,828,000 after purchasing an additional 452,146 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.
Insiders Place Their Bets
In other STERIS news, SVP Cary L. Majors sold 12,828 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total transaction of $3,208,026.24. Following the completion of the transaction, the senior vice president directly owned 11,372 shares of the company's stock, valued at approximately $2,843,909.76. This trade represents a 53.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel A. Carestio sold 17,626 shares of the stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $242.56, for a total value of $4,275,362.56. Following the sale, the chief executive officer owned 51,385 shares of the company's stock, valued at $12,463,945.60. This trade represents a 25.54% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.07% of the company's stock.
STERIS Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th were paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date was Tuesday, June 10th. STERIS's payout ratio is currently 36.77%.
About STERIS
(
Get Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Recommended Stories

Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report